HPI Seminar Series

Health Policy and Insurance Research Seminar Series

Time: Noon - 1:00 PM

Date: Seminars are usually held the 2nd and 4th Wednesday of each month with some exceptions - Please refer to the schedule for exact dates.

Location: Department of Population Medicine (DPM) Inui Conference Room A/B, Landmark Center, 401 Park Drive, Suite 401 East, Boston, MA 02215

Directions

Click here to view the background on the seminars

Archived Seminar Series 2017-2018

Archived Seminar Series 2016-2017

Want to be a part of our mailing list? Click here to Subscribe!

Upcoming HPI Research Seminar Schedule
All Presentations Are Held at Noon-1:00 In The Inui Conference Room

September 12, 2018

Seminar Title

Lauren W.

Lauren Wisk, PhD

Assistant Professor

Instructor in Pediatrics, Harvard Medical School

An Update on Health Insurance and Access to Care for Young Adults Post Health Reform: Policy Gains and New Opportunities

With the passage of the Affordable Care Act (ACA) in 2010, several policies expanded access to health insurance coverage and provided protection against a high cost burden for young adults – a group that previously had the lowest rates of insurance coverage across all ages. Although large gains in coverage have been observed for this group overall as a result of the ACA, certain policies differentially affected vulnerable subgroups and continued attention to addressing the remaining gaps in coverage and access for young adults are warranted.

September 26, 2018

Seminar Title

Dennis Ross-Degnan, ScD

Associate Professor

Harvard Medical School

Dept. of Population Medicine

Director of Research at Harvard Pilgrim Health Care Institute

***Please Note: This Series will begin at 1:00 PM in Conference Room 1***

Interrupted Time Series

This session will be a tutorial aimed for new fellows, but open to all. Dr. Dennis Ross-Degnan will speak about interrupted time series basics, as well as new methods for ITS analyses, such as matching methods.

October 10, 2018

Seminar Title

Mara

Mara Murray Horwitz, MD

Research Fellow

Dept. of Population Medicine

Variation in Primary Care Quality Measures: A Multi-Level Analysis

This study aims to understand how much of the variation in primary care quality measures may be attributed to differences between patients, providers, and clinics. Mara will discuss her collaboration with a local network of outpatient care providers, review early data analysis and results, and engage the audience in discussion about next steps ad potential clinical implications and applications.

October 17, 2018

Seminar Title

Jai Jaime Espin me Espin, PhD

Visiting Professor

Andalusian School of Public Health

How Europe is facing the high cost medicines challenge?

This seminar will be an analysis of the different trends in Europe related to pricing and reimbursement of high cost medicines. The pricing regulations systems, the different reimbursement models, the innovative instruments and the opportunity of using biosimilars will be explained in other to compared with the current pharma policy in the US. The debate will be focus in look for commonalities and differences between the different settings.

October 24, 2018

Seminar Title

Anna

Anna Sinaiko, PhD

Harvard School of Public Health

Dept. of Health Policy and Management

Use of reference-based pricing benefit design to steer patients to low-price imaging providers

In the U.S., health care prices vary widely within local markets; and differences in price have little association with quality. To take advantage of this price variation and decrease health care spending, insurers and employers are trying a variety of benefit designs that aim to steer patients to lower-priced providers, including reference-based pricing benefit design (RBP). We evaluate the impact of RBP for advanced imaging offered by a national commercial health plan.

November 14, 2018

Seminar Title

Oreofe

Oreofe 0. Odejide, MD

Medical Oncology

Dana Farber Cancer Institute

Why are Patients with Blood Cancers Less Likely to Receive Quality End-of-Life Care?

Existing studies demonstrate that patients with blood cancers have high rates of intensive care near death and low rates of timely hospice enrollment – all markers of potentially suboptimal end-of-life care. During this seminar, I will examine factors (patient, physician, policy) that contribute to the current state of end-of-life care in this population.

November 28, 2018

Seminar Title

Huseyin Naci, PhD

Assistant Professor of Health Policy at the London School of Economics and Political Science

Evidence standards for approving cancer medicines in Europe

In this study, we evaluated the characteristics of clinical studies supporting the European Medicines Agency approval of new cancer medicines from 2009 to 2013. In addition, we determined the proportion of drugs with demonstrable benefit on survival or quality of life over available treatment options or placebo, both at time of approval and in the postmarking period. Finally, we investigated the magnitude of benefit of drugs showing a significant improvement on survival in the treatment of cancers.

Published paper: https://www.bmj.com/content/359/bmj.j4530

December 12, 2018

Seminar Title

Kenneth Kehl

Kenneth Kehl, M.D.

Medical Oncology

Dana Farber Cancer Institute

Rapid innovation in the treatment of lung cancer: Real-world impact

The recent incorporation of precision medicine and immunotherapy into the management of advanced lung cancer has rapidly transformed treatment patterns. However, this innovation may not have been implemented equitably in the real world. I will review our efforts to understand implementation patterns to date using administrative data and to more gather evidence regarding the impact of precision medicine from the electronic health record at scale.

January 23, 2019

Seminar Title

Scott Weiner, MD, MPH